Protalix BioTherapeutics
PLX
36 hedge funds and large institutions have $3.4M invested in Protalix BioTherapeutics in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 35 → 36 (+1)
0.03% less ownership
Funds ownership: 0.57% → 0.54% (-0.03%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
24% less capital invested
Capital invested by funds: $4.46M → $3.4M (-$1.06M)
50% less call options, than puts
Call options by funds: $17K | Put options by funds: $34K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$136K |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$52.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$32.4K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$19.1K |
| 5 |
VF
Virtu Financial
New York
|
+$10.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$187K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$71.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$44.9K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$44.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$35.9K |
PLX Hedge Fund Activity: Q2 2018 in Review
36 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2018, worth a combined $3.4M — down 24% from $4.46M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PLX positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $136K. The largest seller was DZ Bank, exiting entirely with an estimated $187K sold.
- 36 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2018, up from 35 in Q1 2018.
- Funds reported $3.4M of Protalix BioTherapeutics stock for Q2 2018, down 24% quarter-over-quarter.
- 4 funds opened new Protalix BioTherapeutics positions in Q2 2018 and 3 closed out, a net change of +1 holder.
- The largest Protalix BioTherapeutics buyer in Q2 2018 was Renaissance Technologies, an estimated $136K added.
- The largest Protalix BioTherapeutics seller in Q2 2018 was DZ Bank, an estimated $187K sold.
Based on aggregated 13F filings for Q2 2018.